Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Danesi

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Therapeutic Drug Monitoring|August 15, 2000
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemiaF Innocenti, R Danesi, C Favre, et al.
British Journal of Cancer|July 18, 2013
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamideP Orlandi, A Fontana, A Fioravanti, et al.
ESMO Open|February 26, 2022
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatmentP Conte, P A Ascierto, G Patelli, et al.
British Journal of Cancer|March 26, 2008
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsG Allegrini, A Falcone, A Fioravanti, et al.
ESMO Open|June 11, 2025
Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)M Del Re, R Roncato, A Argentiero, et al.
British Journal of Cancer|March 17, 2011
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerF Loupakis, C Cremolini, A Fioravanti, et al.
ESMO Open|September 12, 2021
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
The Pharmacogenomics Journal|November 11, 2009
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancerF Toffalorio, E Giovannetti, T De Pas, et al.
British Journal of Cancer|June 30, 2005
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinomaC Bengala, V Guarneri, E Giovannetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2011
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patientsF Crea, L Fornaro, E Paolicchi, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Therapeutic Drug Monitoring|August 15, 2000
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemiaF Innocenti, R Danesi, C Favre, et al.
British Journal of Cancer|July 18, 2013
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamideP Orlandi, A Fontana, A Fioravanti, et al.
ESMO Open|February 26, 2022
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatmentP Conte, P A Ascierto, G Patelli, et al.
British Journal of Cancer|March 26, 2008
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsG Allegrini, A Falcone, A Fioravanti, et al.
ESMO Open|June 11, 2025
Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)M Del Re, R Roncato, A Argentiero, et al.
British Journal of Cancer|March 17, 2011
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancerF Loupakis, C Cremolini, A Fioravanti, et al.
ESMO Open|September 12, 2021
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsM Del Re, C Omarini, L Diodati, et al.
The Pharmacogenomics Journal|November 11, 2009
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancerF Toffalorio, E Giovannetti, T De Pas, et al.
British Journal of Cancer|June 30, 2005
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinomaC Bengala, V Guarneri, E Giovannetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 20, 2011
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patientsF Crea, L Fornaro, E Paolicchi, et al.
Pageof 16